Cryoport downgraded by Stephens with a new price target
$CYRX
Biotechnology: Pharmaceutical Preparations
Health Care
Stephens downgraded Cryoport from Overweight to Equal-Weight and set a new price target of $15.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/24/2025 | $10.00 | Neutral → Buy | UBS |
| 12/19/2024 | $11.00 | Buy | Guggenheim |
| 12/19/2024 | $11.00 | Buy | Canaccord Genuity |
| 8/7/2024 | $20.00 → $8.00 | Buy → Hold | Jefferies |
| 7/31/2024 | $19.00 → $15.00 | Neutral → Buy | B. Riley Securities |
| 5/3/2024 | $22.00 → $19.00 | Buy → Neutral | B. Riley Securities |
| 4/4/2024 | $17.00 → $21.00 | Buy | Jefferies |
| 3/13/2024 | $19.00 → $18.00 | Buy | Needham |
SC 13G - Cryoport, Inc. (0001124524) (Subject)
SC 13G/A - Cryoport, Inc. (0001124524) (Subject)
SC 13G/A - Cryoport, Inc. (0001124524) (Subject)
4 - Cryoport, Inc. (0001124524) (Issuer)
4 - Cryoport, Inc. (0001124524) (Issuer)
4 - Cryoport, Inc. (0001124524) (Issuer)
Commercial Cell & Gene therapy revenue of $7.2 million, up 33% year over yearQ1 2025 revenue from continuing operations of $41.0 million, up 10% year over yearSupporting 711 global clinical trials as of March 31, 2025Strategic partnership with DHL; CRYOPDP divestiture expected to close Q2/Q3 2025NASHVILLE, Tenn., May 7, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) (Cryoport), a global provider of temperature-controlled supply chain solutions for the life sciences sector, today announced financial results for the first quarter (Q1) ended March 31, 2025. Jerrell Shelton, C
NASHVILLE, Tenn., April 24, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global provider of supply chain solutions for the life sciences sector, today announced that the Company will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 7, 2025 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport First Quarter 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p.m. ET on Wednesday,
DHL to acquire 100% of CRYOPDP, a leading specialty courier providing logistics services for clinical trials, biopharma, and cell & gene therapies. This acquisition enhances DHL's capabilities in specialty pharma logistics and supports Group's 2030 strategy to become a leader in life science and healthcare logistics.DHL and Cryoport form strategic partnership to strengthen their respective supply chain services offerings for the global life sciences and healthcare sector.BONN, Germany and NASHVILLE, Tenn., March 31, 2025 /PRNewswire/ -- DHL Group ("DHL"), the world's leading logistics provider, and Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport"), a global provider of supply chain solutions for the
Commercial Cell & Gene therapy revenue of $7.2 million, up 33% year over yearQ1 2025 revenue from continuing operations of $41.0 million, up 10% year over yearSupporting 711 global clinical trials as of March 31, 2025Strategic partnership with DHL; CRYOPDP divestiture expected to close Q2/Q3 2025NASHVILLE, Tenn., May 7, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) (Cryoport), a global provider of temperature-controlled supply chain solutions for the life sciences sector, today announced financial results for the first quarter (Q1) ended March 31, 2025. Jerrell Shelton, C
NASHVILLE, Tenn., April 24, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global provider of supply chain solutions for the life sciences sector, today announced that the Company will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 7, 2025 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport First Quarter 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p.m. ET on Wednesday,
DHL to acquire 100% of CRYOPDP, a leading specialty courier providing logistics services for clinical trials, biopharma, and cell & gene therapies. This acquisition enhances DHL's capabilities in specialty pharma logistics and supports Group's 2030 strategy to become a leader in life science and healthcare logistics.DHL and Cryoport form strategic partnership to strengthen their respective supply chain services offerings for the global life sciences and healthcare sector.BONN, Germany and NASHVILLE, Tenn., March 31, 2025 /PRNewswire/ -- DHL Group ("DHL"), the world's leading logistics provider, and Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport"), a global provider of supply chain solutions for the
SD - Cryoport, Inc. (0001124524) (Filer)
SCHEDULE 13G/A - Cryoport, Inc. (0001124524) (Subject)
SCHEDULE 13G/A - Cryoport, Inc. (0001124524) (Subject)
UBS upgraded Cryoport from Neutral to Buy and set a new price target of $10.00
Guggenheim initiated coverage of Cryoport with a rating of Buy and set a new price target of $11.00
Canaccord Genuity initiated coverage of Cryoport with a rating of Buy and set a new price target of $11.00
Cryoport's CRYOGENE will provide Moffitt with state-of-the-art biorepository services TAMPA, Fla. and NASHVILLE, Tenn., Jan. 14, 2025 /PRNewswire/ -- Moffitt Cancer Center, a leading National Cancer Institute-designated comprehensive cancer center, through its wholly owned subsidiary Speros FL, a 775-acre global innovation life sciences campus, and Cryoport, Inc. (NASDAQ:CYRX), a global leader in supply chain solutions for the life sciences industry, today announced a strategic collaboration that will provide CRYOGENE's state-of-the-art biorepository services to Speros in Pasco County, Florida. Cryoport's CRYOGENE business unit is a leading biorepository for the life sciences industry that i
NASHVILLE, Tenn., March 3, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its Board of Directors has elected Linda Baddour as a member of the Board, effective March 15, 2021. Linda Baddour is a senior executive with over twenty years of experience in healthcare, life sciences and pharmaceuticals. "Our corporate governance underpins all that we do at Cryoport and we are delighted to strengthen our Board as we leverage our newly expanded global footprint and advanced temperature-controlled supply chain platform to spur our growth," said Jerrell She
BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Mr. Martin Schmieg has rejoined the Company as a member of its Board of Directors. Having previously served as a member of BriaCell’s Board of Directors from 2016 to 2019, Mr. Schmieg is a “C” level executive with a diversified background in the global biotech, med-tech and pharmaceutical industries with 40 years of business experience. He currently serves as Co-Founder and CEO of ClearIt, L